Q&A With Former CEO Of Sarepta
Some of the most pressing issues facing the field of drug development today — risks versus benefits, early access to drugs and increasing patient involvement — have been tied up in the story of Sarepta Therapeutics and its ongoing quest for a drug for Duchenne muscular dystrophy.
That’s why, after the sudden resignation of CEO Chris Garabedian a month ago from Cambridge-based Sarepta (Nasdaq: SRPT), I (and I suspect many others) immediately had dozens of questions about what happened at the company. Because the questions don’t pertain to one single company, nor just the community of Duchenne patients and their families. Rather, they matter to everyone affected by rare diseases for which there are no treatments.
Hey, check out all the research scientist jobs. Post your resume today!
That’s why, after the sudden resignation of CEO Chris Garabedian a month ago from Cambridge-based Sarepta (Nasdaq: SRPT), I (and I suspect many others) immediately had dozens of questions about what happened at the company. Because the questions don’t pertain to one single company, nor just the community of Duchenne patients and their families. Rather, they matter to everyone affected by rare diseases for which there are no treatments.
Hey, check out all the research scientist jobs. Post your resume today!